ClinicalTrials.gg
WithdrawnNCT01179594Updated Feb 17, 2017

A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.

A Phase 4 interventional study of entecavir and peginterferon alfa-2a [Pegasys] in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-17.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Why this study was withdrawn
This study was canceled for operational reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.

Enrollment
60th of 61
0 · median 109
Started
2010
with 5 others
Phase 4
33 of 64
2 open now
Registered
32nd of 64
by date
Lead sponsor
4 of 64
Hoffmann-La Roche

Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 60th largest by enrollment of the 61 interventional ones that give a count, is one of 6 that started in 2010, is one of 33 in phase 4, and was the 32nd registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing entecavir in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

This randomized, 2 x 2 factorial, parrallel group study will compare the efficacy and safety of 48 versus 96 weeks of peginterferon alfa-2a [Pegasys], with or without entecavir, in patients with HbeAg negative chronic hepatitis B. Patients will be randomly allocated to receive Pegasys (180mcg subcutaneously weekly) for 48 weeks plus placebo (group A) or entecavir (0,5mg orally daily, group B) during weeks 12-36, or Pegasys (180mcg subcutaneously weekly) for 96 weeks plus placebo (group C) or entecavir (group D) during weeks 12-36. Anticipated time on study treatment is 48 or 96 weeks, with a follow-up of 48 weeks. Target sample size is \<500 patients.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >/= 18 years of age
  • chronic for >/= 6 months
  • HBeAg negative at screening
  • adequate renal function

Exclusion criteria

Exclusion Criteria:

  • antiviral therapy for chronic within the previous 6 months
  • hepatitis A, C, D or infection
  • treatment with systemic acyclovir or famciclovir within the previous 6 months
  • decompensated liver disease (Childs B-C)
  • history or evidence of a medical condition associated with chronic liver disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    A

    Drug: peginterferon alfa-2a [Pegasys] · Drug: placebo

  • Experimental
    B

    Drug: entecavir · Drug: peginterferon alfa-2a [Pegasys]

  • Placebo comparator
    C

    Drug: peginterferon alfa-2a [Pegasys] · Drug: placebo

  • Experimental
    D

    Drug: entecavir · Drug: peginterferon alfa-2a [Pegasys]

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy: HBV-DNA reduction to <10,000 copies/ml (<2,000 IU/ml)

    Time frame: 48 weeks after the end of treatment

Secondary outcomes

  1. Correlation early HBsAg response - response end of treatment/follow-up

    Time frame: every 6 weeks up to week 48, every 12 weeks therafter

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2010; primary completion for Nov 2014, 50 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2010
First posted
Aug 11, 2010
StartEst.
Sep 18, 2010
Primary completionEst.
Nov 2014
CompletionEst.
Nov 2014
Last update
Feb 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01179594
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 11, 2010
Start date
Sep 18, 2010 (estimated)
Primary completion
Nov 2014 (estimated)
Completion
Nov 2014 (estimated)
Last update
Feb 17, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Entecavir

Start the discussion